TVTX - Travere Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

TVTX is currently covered by 13 analysts with an average price target of $30.84. This is a potential upside of $15.6 (102.36%) from yesterday's end of day stock price of $15.24.

Travere Therapeutics's activity chart (see below) currently has 101 price targets and 131 ratings on display. The stock rating distribution of TVTX is 88.57% BUY and 11.43% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 35.18% with an average time for these price targets to be met of 138.8 days.

Highest price target for TVTX is $47, Lowest price target is $20, average price target is $33.25.

Most recent stock forecast was given by ED ARCE from HC WAINWRIGHT on 11-Jun-2025.

Currently out of the existing stock ratings of TVTX, 62 are a BUY (88.57%), 8 are a HOLD (11.43%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$30

$15.69 (109.64%)

$22

13 days ago
(11-Jun-2025)

12/20 (60%)

$15.48 (106.61%)

246

Buy

$30

$15.69 (109.64%)

$30

1 months 8 days ago
(16-May-2025)

9/15 (60%)

$13.2 (78.57%)

198

Hold

$23

$8.69 (60.73%)

$10

1 months 22 days ago
(02-May-2025)

5/6 (83.33%)

$1.85 (8.75%)

141

Buy

$47

$32.69 (228.44%)

$41

2 months 10 days ago
(14-Apr-2025)

2/8 (25%)

$32.17 (216.93%)

264

Buy

$47

$32.69 (228.44%)

$45

2 months 14 days ago
(10-Apr-2025)

4/14 (28.57%)

$33.51 (248.41%)

201

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is TVTX (Travere Therapeutics) average time for price targets to be met?

On average it took 138.8 days on average for the stock forecasts to be realized with a an average price target met ratio 35.18

Which analyst has the current highest performing score on TVTX (Travere Therapeutics) with a proven track record?

ANUPAM RAMA

Which analyst has the most public recommendations on TVTX (Travere Therapeutics)?

Anupam Rama works at JPMORGAN and has 26 price targets and 14 ratings on TVTX

Which analyst is the currently most bullish on TVTX (Travere Therapeutics)?

Vamil Divan with highest potential upside - $32.69

Which analyst is the currently most reserved on TVTX (Travere Therapeutics)?

Tim Lugo with lowest potential downside - -$0

Travere Therapeutics in the News

Travere Therapeutics Reports First Quarter 2025 Financial Results

Submitted sNDA seeking full approval of FILSPARI® (sparsentan) for FSGS in March 2025 U.S. net product sales of FILSPARI totaled $55.9 million in 1Q 2025; 703 new PSFs received in the period FILSPARI was recently converted to full approval for the treatment of IgAN in Europe and the UK Clinical data presented at the National...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?